These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
484 related articles for article (PubMed ID: 21131838)
1. Loss of p16INK4A expression in low-grade ovarian serous carcinomas. Schlosshauer PW; Deligdisch L; Penault-Llorca F; Fatemi D; Qiao R; Yao S; Pearl M; Yang Z; Sheng T; Dong J Int J Gynecol Pathol; 2011 Jan; 30(1):22-9. PubMed ID: 21131838 [TBL] [Abstract][Full Text] [Related]
2. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas. Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429 [TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas]. Shao HL; Shen DH; Xue WC; Li Y; Yu YZ Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760 [TBL] [Abstract][Full Text] [Related]
4. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors. Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733 [TBL] [Abstract][Full Text] [Related]
5. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Mayr D; Hirschmann A; Löhrs U; Diebold J Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438 [TBL] [Abstract][Full Text] [Related]
6. Human papilloma virus (HPV) status, p16INK4a, and p53 overexpression in epithelial malignant and borderline ovarian neoplasms. Giordano G; Azzoni C; D'Adda T; Rocco A; Gnetti L; Froio E; Merisio C; Melpignano M Pathol Res Pract; 2008; 204(3):163-74. PubMed ID: 18180113 [TBL] [Abstract][Full Text] [Related]
7. Expression of p53, p21WAF1/CIP1, p16INK4A and Ki-67 proteins in serous ovarian tumors. Buchynska LG; Nesina IP; Yurchenko NP; Bilyk OO; Grinkevych VN; Svintitsky VS Exp Oncol; 2007 Mar; 29(1):49-53. PubMed ID: 17431389 [TBL] [Abstract][Full Text] [Related]
8. Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Bösmüller H; Fischer A; Pham DL; Fehm T; Capper D; von Deimling A; Bonzheim I; Staebler A; Fend F Hum Pathol; 2013 Mar; 44(3):329-35. PubMed ID: 23089489 [TBL] [Abstract][Full Text] [Related]
9. Progressive loss of selenium-binding protein 1 expression correlates with increasing epithelial proliferation and papillary complexity in ovarian serous borderline tumor and low-grade serous carcinoma. Zhang C; Wang YE; Zhang P; Liu F; Sung CJ; Steinhoff MM; Quddus MR; Lawrence WD Hum Pathol; 2010 Feb; 41(2):255-61. PubMed ID: 19896693 [TBL] [Abstract][Full Text] [Related]
11. The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis. Dehari R; Kurman RJ; Logani S; Shih IeM Am J Surg Pathol; 2007 Jul; 31(7):1007-12. PubMed ID: 17592266 [TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Chiesa-Vottero AG; Malpica A; Deavers MT; Broaddus R; Nuovo GJ; Silva EG Int J Gynecol Pathol; 2007 Jul; 26(3):328-33. PubMed ID: 17581420 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of MTAP immunohistochemistry loss of expression in ovarian serous borderline tumors as a potential marker for prognosis and progression. Nilforoushan N; Moatamed NA Ann Diagn Pathol; 2020 Oct; 48():151582. PubMed ID: 32866902 [TBL] [Abstract][Full Text] [Related]
14. Analysis of p53, p16(INK4a), pRb and Cyclin D1 expression and human papillomavirus in primary ovarian serous carcinomas. Bilyk OO; Pande NT; Buchynska LG Exp Oncol; 2011 Sep; 33(3):150-6. PubMed ID: 21956468 [TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of 103 ovarian serous and mucinous tumors. Vereczkey I; Serester O; Dobos J; Gallai M; Szakács O; Szentirmay Z; Tóth E Pathol Oncol Res; 2011 Sep; 17(3):551-9. PubMed ID: 21136228 [TBL] [Abstract][Full Text] [Related]
16. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A; Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818 [TBL] [Abstract][Full Text] [Related]
17. Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors. Hayashi Y; Sasaki H; Takeshita S; Nishikawa R; Nishikawa H; Arakawa A; Yamashita Y; Takahashi S; Sugiura-Ogasawara M Oncol Rep; 2014 Nov; 32(5):1815-9. PubMed ID: 25174456 [TBL] [Abstract][Full Text] [Related]
18. Is Invasive Micropapillary Serous Carcinoma a Low-grade Carcinoma? Ohishi Y; Imamura H; Aman M; Shida K; Kaku T; Kato K; Oda Y Int J Gynecol Pathol; 2016 Jan; 35(1):56-65. PubMed ID: 26166721 [TBL] [Abstract][Full Text] [Related]